Literature DB >> 27892945

Therapy of pediatric ALL relapsing after allogeneic transplant: how to make progress with limited patient numbers?

M Bierings1.   

Abstract

Entities:  

Mesh：

Year:  2016        PMID： 27892945     DOI： 10.1038/bmt.2016.276

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


× No keyword cloud information.
  7 in total

1.  Level of minimal residual disease prior to haematopoietic stem cell transplantation predicts prognosis in paediatric patients with acute lymphoblastic leukaemia: a report of the Pre-BMT MRD Study Group.

Authors:  O Krejci; V H J van der Velden; P Bader; H Kreyenberg; N Goulden; J Hancock; M W Schilham; A Lankester; T Révész; T Klingebiel; J J M van Dongen
Journal:  Bone Marrow Transplant       Date:  2003-10       Impact factor: 5.483

2.  Chimeric antigen receptor T cells for sustained remissions in leukemia.

Authors:  Shannon L Maude; Noelle Frey; Pamela A Shaw; Richard Aplenc; David M Barrett; Nancy J Bunin; Anne Chew; Vanessa E Gonzalez; Zhaohui Zheng; Simon F Lacey; Yolanda D Mahnke; Jan J Melenhorst; Susan R Rheingold; Angela Shen; David T Teachey; Bruce L Levine; Carl H June; David L Porter; Stephan A Grupp
Journal:  N Engl J Med       Date:  2014-10-16       Impact factor: 91.245

3.  Long-term follow-up of imatinib in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: Children's Oncology Group study AALL0031.

Authors:  K R Schultz; A Carroll; N A Heerema; W P Bowman; A Aledo; W B Slayton; H Sather; M Devidas; H W Zheng; S M Davies; P S Gaynon; M Trigg; R Rutledge; D Jorstad; N Winick; M J Borowitz; S P Hunger; W L Carroll; B Camitta
Journal:  Leukemia       Date:  2014-01-20       Impact factor: 11.528

4.  Minimal residual disease status before allogeneic bone marrow transplantation is an important determinant of successful outcome for children and adolescents with acute lymphoblastic leukemia.

Authors:  C J Knechtli; N J Goulden; J P Hancock; V L Grandage; E L Harris; R J Garland; C G Jones; A W Rowbottom; L P Hunt; A F Green; E Clarke; A W Lankester; J M Cornish; D H Pamphilon; C G Steward; A Oakhill
Journal:  Blood       Date:  1998-12-01       Impact factor: 22.113

5.  Pediatric posttransplant relapsed/refractory B-precursor acute lymphoblastic leukemia shows durable remission by therapy with the T-cell engaging bispecific antibody blinatumomab.

Authors:  Patrick Schlegel; Peter Lang; Gerhard Zugmaier; Martin Ebinger; Hermann Kreyenberg; Kai-Erik Witte; Judith Feucht; Matthias Pfeiffer; Heiko-Manuel Teltschik; Christina Kyzirakos; Tobias Feuchtinger; Rupert Handgretinger
Journal:  Haematologica       Date:  2014-04-11       Impact factor: 9.941

6.  Imatinib after induction for treatment of children and adolescents with Philadelphia-chromosome-positive acute lymphoblastic leukaemia (EsPhALL): a randomised, open-label, intergroup study.

Authors:  Andrea Biondi; Martin Schrappe; Paola De Lorenzo; Anders Castor; Giovanna Lucchini; Virginie Gandemer; Rob Pieters; Jan Stary; Gabriele Escherich; Myriam Campbell; Chi-Kong Li; Ajay Vora; Maurizio Aricò; Silja Röttgers; Vaskar Saha; Maria Grazia Valsecchi
Journal:  Lancet Oncol       Date:  2012-08-14       Impact factor: 41.316

7.  A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trial.

Authors:  Rob Pieters; Martin Schrappe; Paola De Lorenzo; Ian Hann; Giulio De Rossi; Maria Felice; Liisa Hovi; Thierry LeBlanc; Tomasz Szczepanski; Alice Ferster; Gritta Janka; Jeffrey Rubnitz; Lewis Silverman; Jan Stary; Myriam Campbell; Chi-Kong Li; Georg Mann; Ram Suppiah; Andrea Biondi; Ajay Vora; Maria Grazia Valsecchi
Journal:  Lancet       Date:  2007-07-21       Impact factor: 79.321
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.